Adaptable Aspirin Study Login
Searching for Adaptable Aspirin Study Login page? Just a click to access Adaptable Aspirin Study Login through official links provided below on our site.
The purpose of ADAPTABLE is to find the best dose of aspirin, 81 mg or 325 mg, for people with known or existing heart disease to prevent death or another heart attack or stroke. What did we learn? With your valuable contribution, we successfully completed a virtual trial with 15,076 participants.
-
The Optimal Dose of Aspirin
For more than 40 years, aspirin has been a key therapy for patients with cardiovascular disease used to reduce the risk of a future cardiovascular event such as a heart attack or stroke. For the millions of Americans with heart disease, doctors variably recommend high-dose (325 mg) or low-dose (81 mg) aspirin with no clear preference for either …
-
Participate
The ADAPTABLE study has enrolled more than 15,000 patients with heart disease. Eligible participants in ADAPTABLE were identified from large health systems that are part of PCORnet,® The National Patient-Centered Clinical Research Network.
-
Meet the Adaptors
Meet The Adaptors In ADAPTABLE, the role of the patient has shifted from participant to partner. Adaptors are patient representatives who have been involved in ADAPTABLE from the beginning. Working with the study team, Adaptors helped design the protocol, consent form, study portal, and study materials. Adaptors will be integral in disseminating study updates and … Continue reading Meet the …
-
News
ADAPTABLE patient partners, also known as Adaptors, provide input to the study team at every critical step in the research process. Adaptors are passionate about patient-centered research and draw on their personal work and life experiences to improve the study participant experience for current and future research participants.
-
Newsletter
How ADAPTABLE Study fits in the recent guidelines on use of aspirin in cardiovascular diseases On March 17, 2019, the American College of Cardiology and the American Heart Association jointly published recommendations based on recent studies on …
-
Study Progress
On May 15, 2021, the ADAPTABLE study team shared results in a late-breaking clinical trials session during the 70 th annual American College of Cardiology Scientific Session. The results, which were simultaneously published in the New England Journal of Medicine, provide insight into which dose may be best for most patients. Read more about the results here.
ADAPTABLE, the Aspirin Study – A Patient-Centered Trial ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) is a three-year pragmatic clinical trial that will compare the effectiveness of two different daily doses of aspirin widely used to prevent heart attacks and strokes in individuals living with heart disease.
ADAPTABLE – The Aspirin Study March 2017 – The Sheps Center is partnering with the School of Medicine and TraCS to recruit patients for a pragmatic clinical trial comparing low dose (81mg) aspirin to regular strength (325mg) aspirin among patients with known heart disease. We are recruiting UNC HealthCare patients across the state.
The first clinical trial, called Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE), will randomly assign 20,000 subjects with established coronary heart disease to either low dose (81 mg) or high dose (325 mg) and should be able to finally answer which dosage of aspirin is best for patients with established cardiovascular disease.
May 15, 2021Patients with ASCVD were randomized to aspirin 81 mg (n = 7,540) versus aspirin 325 mg (n = 7,536). Total number of enrollees: 15,076. Duration of follow-up: 26.2 months. Mean patient age: 68 years. Percentage female: 31%. Percentage with diabetes: 38%. Inclusion criteria: Patients with CVD, defined as: 1) prior myocardial infarction (MI), 2) prior coronary revascularization, 3) prior coronary angiogram with ≥75% coronary stenosis, or 4) history of chronic ischemic heart disease, coronary …
May 15, 2021ADAPTABLE randomized 15,076 people with existing cardiovascular disease to receive either baby aspirin (81 mg) or regular strength aspirin (325 mg). Although aspirin is the most commonly used medication for people with cardiovascular disease to prevent a heart attack or stroke, there has been little evidence as to which dose provides the best protection while also minimizing risk of bleeding.
Comparing Effectiveness of Two Daily Doses of Aspirin Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) is a study that compared the effectiveness of two daily doses of aspirin widely used to prevent heart attacks and strokes in individuals living with heart disease.
Feb 15, 2022Comparisons are aspirin 81 mg vs. aspirin 325 mg. Primary Outcomes Effectiveness Death or hospitalization secondary to stroke or MI: 7.28% vs. 7.51% (HR 1.02; 95% CI 0.91 – 1.14; P = 0.75) Safety Hospitalization for major bleeding requiring blood transfusion: 0.63% vs. 0.60% (HR 1.18 CI 0.79 – 1.77; P = 0.41) Secondary Outcomes Death from any cause
Sep 1, 2021Aspirin is a mainstay therapy for patients with atherosclerotic cardiovascular disease, but there are unanswered questions about the best dosage. ADAPTABLE studied the effectiveness and safety of the two most common aspirin doses, and it served as the demonstration project for clinical trials in the Patient-Centered Outcomes Research network (PCORnet), funded by the Patient-Centered Outcomes Research Institute (PCORI).
May 15, 2021we designed and conducted adaptable (aspirin dosing: a patient-centric trial assessing benefits and long-term effectiveness), an open-label, pragmatic, randomized, controlled trial, to assess…
ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) is a PCORI-funded clinical study comparing the benefits and risks of low-dose aspirin to regular-strength in people with heart disease.
The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. Current Cardiology Reports. August 2016. View Journal Publication. … The ADAPTABLE Study. PCORI. 1333 New Hampshire Avenue NW, Suite 1200 Washington, DC 20036 Phone: (202) 827-7700 | Fax: (202) 355-9558 [email protected] …
ADAPTABLE ADAPTABLE is a clinical trial comparing the effectiveness of 81mg versus 325mg daily doses of aspirin to prevent heart attack and stroke in people living with heart disease. Results are now available on the study website.
The ADAPTABLE Study: Patient-Centered Aspirin. April 6, 2022 | C. Michael Gibson discusses aspirin dosing and long-term effectivness with Schuyler Jones and Greg Merritt. … Login; Search TCTMD Search. Close Search. Submit an Event. Contact Email. Contact Phone Number. Event Name. Location. Start Date. Start Time. End Date. End Time. Event …
ADAPTABLE is a pragmatic clinical trial in which 15,000 patients who are at high risk for ischemic events will be randomly assigned in a 1:1 ratio to receive an aspirin dose of 81 mg/day vs. 325 mg/day. Study participants will be enrolled over 38 months. Maximum follow-up will be 50 months. The purpose of the study is to identify the optimal dose of aspirin for secondary prevention in patients with Atherosclerotic cardiovascular disease (ASCVD).
Background: ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) is a pragmatic clinical trial examining high-dose versus low-dose aspirin among patients with cardiovascular disease. ADAPTABLE is leveraging novel approaches for clinical trial conduct to expedite study completion and reduce costs.
May 12, 2021Before the study, most patients (96%) were taking aspirin, and of these, most (85%) were taking low-dose aspirin (81 mg). Of note, there was a significantly higher rate of dose switching in the high-dose (325 mg) group, with 41.6% switching the dose at least once, compared with only 7.1% of the low-dose group.
Study co-director Adrian Hernandez, MD, MHS, discusses the important questions to be answered by the ADAPTABLE aspirin dosage study and how it will be conduc…
Jun 4, 2022People with cardiovascular disease who took aspirin to lower their chances of having a heart attack or stroke experienced similar health benefits, including reduced death and hospitalization, whether they took a high or low dose of the medication, according to findings from this study released in May 2021.
May 15, 2021A new study has returned an answer to the age-old question: what is the optimal aspirin dose for prevention of cardiovascular events? Results of the ADAPTABLE study indicate there were no major differences in events or major bleeding in patients with existing cardiovascular disease, regardless of whether they were taking the 81 and 325 mg daily doses of aspirin, but investigators noted …
ADAPTABLE Study About See all A patient-centered pragmatic study seeking the optimal dose of aspirin for patients with heart disease. ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) is comparing two daily doses of aspirin widely us… See more 190 peoplelike this 229 people follow this
May 15, 2021Pragmatic Trials — Need for ADAPTABLE Design. Colin Baigent, F.Med.Sci. The publication in the Journal of the results of ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and …
Oct 12, 2021Duke CTSI announces the publication of a new case study documenting the multi-site ADAPTABLE Study with Duke PIs Adrian Hernandez, MD, and W. Schuyler Jones, MD. This patient-centered clinical trial studied the effectiveness and safety of the two most common aspirin doses for cardiovascular disease. Find out how the project was designed and carried out, see a timeline of the steps involved …
Sep 13, 2021ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness) is the first major multicenter research project to be conducted in National Patient-Centered Clinical Research Network. … and study policy including compensation of participants. Although it was “too late” for some suggested modifications …
Study co-chair Dr. Bob Harrington, answers why the ADAPTABLE aspirin dosage study is important.
ADAPTABLE The Aspirin Study Non-Internet Subject Database Training December 14, 2016 . Access to ADAPTABLE Web Portal To request a site user account: § Contact DCRI Coordinating Center § Provide NAME, EMAIL ADDRESS, ROLE of site coordinator needing access You will receive an email from Mytrus confirming your user account set-up Go to …
May 15, 2021ADAPTABLE was an opportunity to accomplish a large-scale study in a generalizable manner: directly involve patients, partner with them, and cocreate the program, noted Schuyler Jones, MD …
